原发手术切除的口咽鳞状细胞癌治疗延迟:全国基准与生存关联
该回顾性横断面分析纳入国家癌症数据库3708例手术治疗口咽癌患者,中位诊断至治疗开始、手术至放疗、放疗时长、总治疗包和诊断至治疗结束间隔分别为27、42、47、90和106天。延迟总治疗包和诊断至治疗结束间隔与生存下降相关,手术至放疗延迟仅在HPV阴性患者中与生存下降相关。
要点
- 中位治疗间隔可作为全国基准用于质量比较
- 总治疗包和诊断至治疗结束延迟与生存下降相关
- HPV阴性和阳性患者应应用不同基准
核心结论
- 延迟总治疗包和诊断至治疗结束间隔与生存下降独立相关,且HPV分层后仍存在。
- 手术至放疗延迟仅在HPV阴性患者中与生存下降相关。
研究设计与样本
- 回顾性横断面分析,纳入国家癌症数据库3708例手术治疗口咽癌患者。
主要发现
- 中位诊断至治疗开始、手术至放疗、放疗时长、总治疗包和诊断至治疗结束间隔分别为27、42、47、90和106天。
关键数值与推荐
- 中位间隔:诊断至治疗开始27天,手术至放疗42天,放疗时长47天,总治疗包90天,诊断至治疗结束106天。
- HPV阴性和阳性患者应使用不同的治疗延迟基准。
临床怎么用
- 可将中位间隔作为全国基准,供机构与同行比较质量。
- 对HPV阴性患者应特别关注手术至放疗间隔,避免延迟。
局限性
- 回顾性研究设计可能存在残留混杂。
- 仅纳入 Commission on Cancer 认证机构患者,外推性受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To characterize treatment delays in surgically treated oropharyngeal cancer, identify factors associated with delays, and associate delays with survival. STUDY DESIGN: Retrospective cross-sectional analysis. SETTING: Commission on Cancer-accredited institutions. SUBJECTS AND METHODS: We identified patients in the National Cancer Database with surgically treated oropharyngeal cancer. We characterized the durations of diagnosis-to-treatment initiation, surgery-to-radiation treatment, radiation treatment duration, total treatment package, and diagnosis-to-treatment end intervals as medians. We associated delays with patient, tumor, and treatment factors via multivariable logistic regression analysis and with overall survival by Cox proportional hazards regression. RESULTS: In total, 3708 patients met inclusion criteria. Median durations of diagnosis-to-treatment initiation, surgery-to-radiation treatment, radiation treatment duration, total treatment package, and diagnosis-to-treatment end intervals were 27, 42, 47, 90, and 106 days, respectively. Medicaid and human papillomavirus (HPV) negativity were associated with delays. Delayed total treatment package and diagnosis-to-treatment end intervals were associated with decreased survival (hazard ratio [HR] = 1.81 [1.29-2.54], P = .001 and HR = 1.97 [1.39-2.78], P < .001, respectively); this was maintained following HPV stratification. Delays in the surgery-to-radiation treatment interval were associated with decreased overall survival in HPV-negative but not HPV-positive patients (HR = 2.05 [1.19-3.52], P = .010 and HR = 1.15 [0.74-1.80], P = .535, respectively). Diagnosis-to-treatment initiation and radiation treatment duration were not associated with overall survival in the overall cohort (HR = 1.21 [0.86-1.72], P = .280 and HR = 1.40 [0.99-1.99], P = .061, respectively); however, following stratification, delayed radiation treatment duration approached significance in HPV-negative but not HPV-positive patients (HR = 1.60 [0.96-2.68], P = .072 and HR = 1.35 [0.84-2.18], P = .220). CONCLUSION: Treatment durations identified here can serve as national benchmarks and for institutions to compare quality to their peers. Distinct benchmarks should be applied to HPV-negative and HPV-positive patients.
引用
- Morse E, Judson B, Husain Z, et al. Treatment Delays in Primarily Resected Oropharyngeal Squamous Cell Carcinoma: National Benchmarks and Survival Associations. Otolaryngol Head Neck Surg. 2018. PMID: 30060700. doi:10.1177/0194599818779052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。